Rigorous Safety Monitoring Central To NK Cell Therapy Development

In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics. emphasized that safety is a key advantage of NK cell therapies over T cells, as NK cells have a lower risk of severe toxicities demonstrated in both preclinical models and patient treatments. She shared that her team integrates comprehensive safety monitoring into trial design to ensure patient well-being and regulatory confidence.